Seres Therapeutics (MCRB) to Release Earnings on Wednesday

Seres Therapeutics (NASDAQ:MCRB) will likely be issuing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to announce earnings of ($2.1850) per share and revenue of $0.1790 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 8:30 AM ET.

Seres Therapeutics (NASDAQ:MCRB) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported ($2.08) earnings per share for the quarter, missing the consensus estimate of ($1.88) by ($0.20). The company had revenue of $0.36 million for the quarter, compared to analysts’ expectations of $0.36 million. On average, analysts expect Seres Therapeutics to post $-6 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Seres Therapeutics Stock Up 4.1%

Shares of MCRB stock opened at $5.03 on Tuesday. Seres Therapeutics has a 52 week low of $4.59 and a 52 week high of $29.98. The stock has a market capitalization of $48.69 million, a PE ratio of -0.97 and a beta of 0.20. The firm has a 50 day moving average of $6.38 and a two-hundred day moving average of $8.70.

Wall Street Analysts Forecast Growth

MCRB has been the topic of a number of recent research reports. Zacks Research raised Seres Therapeutics to a “hold” rating in a research report on Tuesday, June 23rd. HC Wainwright began coverage on Seres Therapeutics in a report on Tuesday, June 23rd. They issued a “buy” rating and a $12.00 target price for the company. Weiss Ratings cut Seres Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. Finally, Wall Street Zen upgraded Seres Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 6th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Seres Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $17.00.

Institutional Investors Weigh In On Seres Therapeutics

A number of large investors have recently modified their holdings of MCRB. Invesco Ltd. raised its holdings in shares of Seres Therapeutics by 37.5% in the 4th quarter. Invesco Ltd. now owns 14,360 shares of the biotechnology company’s stock valued at $214,000 after purchasing an additional 3,918 shares in the last quarter. ExodusPoint Capital Management LP acquired a new position in shares of Seres Therapeutics during the fourth quarter worth $190,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Seres Therapeutics during the fourth quarter worth $214,000. Barclays PLC increased its holdings in Seres Therapeutics by 427.8% in the fourth quarter. Barclays PLC now owns 7,432 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 6,024 shares during the last quarter. Finally, State Street Corp increased its holdings in Seres Therapeutics by 14.0% in the fourth quarter. State Street Corp now owns 33,901 shares of the biotechnology company’s stock valued at $504,000 after buying an additional 4,170 shares during the last quarter. 59.34% of the stock is owned by hedge funds and other institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.